Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy - Report - MDSpire
Advertisement
Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy
Clinical Report: Utilizing Contrast-Enhanced Ultrasonography in NSCLC
Overview
This report discusses the use of contrast-enhanced ultrasonography (CEUS) to evaluate a newly identified contralateral pulmonary lesion in a patient undergoing chemoimmunotherapy for non-small cell lung cancer (NSCLC). CEUS provided valuable information that suggested an inflammatory process rather than malignancy, which was later confirmed by clinical follow-up.
Background
The emergence of new pulmonary lesions during chemoimmunotherapy for NSCLC presents a diagnostic challenge, as these lesions may indicate tumor progression, infection, or benign processes. Traditional imaging methods like computed tomography (CT) may not always provide sufficient clarity for diagnosis. CEUS offers real-time perfusion assessment, potentially enhancing the diagnostic accuracy for peripheral pulmonary lesions.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
CEUS demonstrated rapid hyperenhancement in the pulmonary arterial phase of the lesion.
The lesion exhibited relatively homogeneous internal enhancement and slight persistent hyperenhancement in the venous phase.
Clinical follow-up showed marked regression of the lesion after anti-infective treatment.
CEUS is most effective when used in conjunction with clinical, laboratory, and imaging data.
New pulmonary lesions during therapy require careful evaluation to differentiate between malignancy and other processes.
Clinical Implications
Healthcare professionals should consider integrating CEUS into the diagnostic workflow for patients with newly detected pulmonary lesions during chemoimmunotherapy. This approach may improve the differentiation between inflammatory and malignant processes, potentially avoiding unnecessary interventions.
Conclusion
The case illustrates the adjunctive role of CEUS in evaluating pulmonary lesions in NSCLC patients undergoing treatment. Its integration with other clinical data enhances diagnostic confidence and patient management.
Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)
